AstraZeneca Scores CHMP Hat Trick With Tagrisso Top Of The Nods
This article was originally published in Scrip
AstraZeneca PLC won three positive opinions in the latest pronouncements from the European Medicines Agency's top drug advisory panel, giving fresh support to the British pure pharma's expanding pipeline.
You may also be interested in...
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.